BR0308407A - Compostos de quinazolina úteis em terapia - Google Patents

Compostos de quinazolina úteis em terapia

Info

Publication number
BR0308407A
BR0308407A BR0308407-8A BR0308407A BR0308407A BR 0308407 A BR0308407 A BR 0308407A BR 0308407 A BR0308407 A BR 0308407A BR 0308407 A BR0308407 A BR 0308407A
Authority
BR
Brazil
Prior art keywords
alkyl
het
cycloalkyl
optionally substituted
useful
Prior art date
Application number
BR0308407-8A
Other languages
English (en)
Inventor
Julian Blagg
Michael Jonathan Fray
Mark Llewelllyn Lewis
John Paul Mathias
Mark Henryck Stefanniak
Alan Stobie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0308407A publication Critical patent/BR0308407A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTOS DE QUINAZOLINA úTEIS EM TERAPIA". Compostos de fórmula (I) ou seus sais ou solvatos farmaceuticamente aceitáveis, em que: R^ 1^ representa alquila-C~ 1-4~; R^ 2^ representa halogênio, alquila-C~ 1-4~, cicloalquila-C~ 3-6~, cicloalquilóxi-C~ 3-6~, -SO~ 2~(alquila-C~ 1-4~), alquilóxi-C~ 1-4~ opcionalmente substituído, Het ou -OHet; R^ 3^ representa um grupo bicíclico de fórmula em que X e Y são selecionados de C e N, desde que pelo menos um deles seja C; O anel A em conjunto com X e Y representa um anel aromático de 5 ou 6 membros que contém 0, 1, 2 ou 3 átomos de azoto no anel; n é 0, 1 ou 2; L representa uma ligação direta, alquileno-C~ 1-4~ ou alcoxialquileno-C~ 1-4~; R^ 4^ representa H, -NR^ 5^R^ 6^ cicloalquila-C~ 3-6~, -OR^ 7^, Het^ 1^ ou Het^ 4^; R^ 5^ e R^ 6^ são selecionados de forma independente de H, cicloalquila-C~ 3-6~, cicloalquila-C~ 3-6~-alquileno-C~ 1-4~, -SO~ 2~ (alquila-C~ 1-4~) e alquila-C~ 1-4~ opcionalmente substituído; R^ 7^ é-selecionado de H, alquila-C~ 1-4~, alcoxialquila-C~ 1-4~, cicloalquila-C~ 3-6~, Het^ 2^ e alquila-C~ 1-4~-Het^ 3^; R^ 8^ é H ou alquila-C~ 1-4~-; Het, Het^ 1^ Het^ 2^ e Het~ 3^ representam de forma independente um grupo heterocíclico saturado de 4 a 7 membros opcionalmente substituído que pode ser mono- ou bicíclico e que contém um ou mais heteroátomos selecionados de N, O ou S; Het^ 4^ representa um grupo heterocíclico, insaturado de 5 ou 6 membros opcionalmente substituído que contém um ou mais heteroátomos selecionados de N, O ou S; R^ 9^ é H ou alquila-C~ 1-4~; R^ 10^ e R^ 11^ são selecionados de forma independente de H e alquila-C~ 1-4~; são úteis para o tratamento de hipertensão, enfarto do miocárdio, disfunção eréctil masculina (MED), hiperlipidemia, arritmia cardíaca, glaucoma e hiperplasia prostática benigna (BPH). São igualmente úteis para o tratamento da disfunção da excitação sexual feminina (FSAD).
BR0308407-8A 2002-03-14 2003-03-05 Compostos de quinazolina úteis em terapia BR0308407A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206033.3A GB0206033D0 (en) 2002-03-14 2002-03-14 Compounds useful in therapy
PCT/IB2003/000998 WO2003076427A1 (en) 2002-03-14 2003-03-05 Quinazoline compounds useful in therapy

Publications (1)

Publication Number Publication Date
BR0308407A true BR0308407A (pt) 2005-01-11

Family

ID=9932974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308407-8A BR0308407A (pt) 2002-03-14 2003-03-05 Compostos de quinazolina úteis em terapia

Country Status (19)

Country Link
US (1) US6936619B2 (pt)
EP (1) EP1483257B1 (pt)
JP (1) JP2005532275A (pt)
AR (1) AR038949A1 (pt)
AT (1) ATE339414T1 (pt)
AU (1) AU2003209594A1 (pt)
BR (1) BR0308407A (pt)
CA (1) CA2479016A1 (pt)
DE (1) DE60308332T2 (pt)
ES (1) ES2271618T3 (pt)
GB (1) GB0206033D0 (pt)
GT (1) GT200300059A (pt)
HN (1) HN2003000100A (pt)
MX (1) MXPA04008939A (pt)
PA (1) PA8569501A1 (pt)
PE (1) PE20040265A1 (pt)
TW (1) TW200305420A (pt)
UY (1) UY27711A1 (pt)
WO (1) WO2003076427A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ES2270143T3 (es) * 2002-08-07 2007-04-01 Novartis Ag Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona.
US20040132728A1 (en) * 2002-09-17 2004-07-08 Pfizer Inc Combinations of atorvastatin and alpha1adrenergic receptor antagonists
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
AU2004255585A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
EP1595881A1 (en) * 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
CA2606760C (en) 2005-05-04 2014-12-23 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions
EP1790646A1 (fr) * 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
ES2427999T3 (es) 2007-04-17 2013-11-05 Evotec Ag Compuestos heterocíclicos 2-cianofenil-condensados y composiciones y usos de los mismos
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
MY146924A (en) 2007-06-21 2012-10-15 Cara Therapeutics Inc Substituted imidazoheterocycles
WO2009011904A1 (en) * 2007-07-19 2009-01-22 Renovis, Inc. Compounds useful as faah modulators and uses thereof
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2010014666A2 (en) 2008-07-31 2010-02-04 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
US8691827B2 (en) 2009-08-17 2014-04-08 Merck Sharp & Dohme Corp. Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PE20191204A1 (es) 2012-08-06 2019-09-10 Firmenich Incorporated Modificador del sabor dulce
WO2014060852A2 (en) * 2012-10-15 2014-04-24 Resverlogix Corp. Compounds useful in the synthesis of benzamide compounds
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
TN2016000254A1 (en) * 2013-12-20 2017-10-06 Esteve Labor Dr Fused imidazolyl derivatives, their preparation and use as medicaments.
CA2943889A1 (en) * 2014-05-28 2015-12-03 F. Hoffmann-La Roche Ag 5-oxa-2-azabicyclo[2.2.2]octan-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives as taar1 modulators
WO2016147053A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
CN105237455A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 一种3-取代氮杂环丁烷的制备方法
MY196319A (en) 2015-12-17 2023-03-24 Merck Patent Gmbh Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
JP6950534B2 (ja) * 2016-01-29 2021-10-13 小野薬品工業株式会社 テトラヒドロナフタレン誘導体
WO2018031434A1 (en) * 2016-08-08 2018-02-15 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085213A (en) * 1976-01-28 1978-04-18 Pfizer Inc. Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物

Also Published As

Publication number Publication date
MXPA04008939A (es) 2004-11-26
CA2479016A1 (en) 2003-09-18
DE60308332D1 (de) 2006-10-26
PE20040265A1 (es) 2004-05-01
GT200300059A (es) 2003-10-15
GB0206033D0 (en) 2002-04-24
EP1483257B1 (en) 2006-09-13
EP1483257A1 (en) 2004-12-08
UY27711A1 (es) 2003-10-31
WO2003076427A1 (en) 2003-09-18
US6936619B2 (en) 2005-08-30
ES2271618T3 (es) 2007-04-16
HN2003000100A (es) 2003-12-15
ATE339414T1 (de) 2006-10-15
DE60308332T2 (de) 2007-01-11
PA8569501A1 (es) 2003-12-10
AU2003209594A1 (en) 2003-09-22
US20040029859A1 (en) 2004-02-12
TW200305420A (en) 2003-11-01
JP2005532275A (ja) 2005-10-27
AR038949A1 (es) 2005-02-02
WO2003076427A8 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
BR0308407A (pt) Compostos de quinazolina úteis em terapia
NZ336302A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
PE20080557A1 (es) Compuestos de azabencimidazolilo con actividad sobre los receptores glutamato
BR0108118A (pt) Inibidores da catepsina k de dipeptìdeo nitrila
PE20010736A1 (es) PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA
ATE362912T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
AR040566A1 (es) Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
EA200300449A1 (ru) Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы
GB9213623D0 (en) Therapeutic agents
PE20001305A1 (es) Derivados de pirazolopiridina
BR0004779A (pt) Compostos farmaceuticamente ativos
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
NO20001624D0 (no) Tablettformulering med vedvarende frigivelse for behandling av Parkinsons sykdom
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
ATE109481T1 (de) Diazinderivate als angiotensin ii rezeptor antagonisten.
EA199901112A1 (ru) Способы лечения тромботических нарушений
ATE348101T1 (de) Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion
AR036327A1 (es) Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados
CO5271666A1 (es) Derivados de pirimidina
NO20024364D0 (no) Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
AR024146A1 (es) Derivados de 4-fenil-pirimidina
NO20013334L (no) Anvendelse av imidazo [1,5-A]-pyrido[3,2-E]-pyrazinoner som legemidler
DE60014681D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
MXPA01012558A (es) Compuestos de n-bencensulfonil l-prolina como antagonista de bradiquinina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.